An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients

被引:27
作者
Alexis, JB
Martinez, AE
Lutzky, J
机构
[1] Mt Sinai Med Ctr, Dept Pathol & Lab Med, Miami, FL 33140 USA
[2] Miami Univ, Sch Med, Miami, FL 33140 USA
[3] Mt Sinai Med Ctr, Comprehens Canc Ctr, Miami, FL 33140 USA
[4] Mt Sinai Med Ctr, Arkadi M Rywilin MD Dept Pathol & Lab Med, Miami, FL 33140 USA
关键词
chemotherapy; c-kit; immunohistochemistry; melanoma;
D O I
10.1097/00008390-200508000-00008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In order to determine whether imatinib mesylate (Gleevec), a tyrosine kinase inhibitor that binds the CD-117 (c-kit) receptor, may be of value in the treatment of malignant melanoma, an immunohistochemical analysis of 40 cases of primary and metastatic melanoma was undertaken. Thirty-five of the 40 cases showed 1 + or stronger labelling for CD-117 (up to a maximum of 4 +). Three patients with neoplasms showing 4 + staining were selected for imatinib therapy. None responded. c-kit (CD-117) expression in melanoma appears to be common; however, the value of imatinib therapy remains to be proven.
引用
收藏
页码:283 / 285
页数:3
相关论文
共 12 条
  • [1] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
    Demetri, GD
    von Mehren, M
    Blanke, CD
    Van den Abbeele, AD
    Eisenberg, B
    Roberts, PJ
    Heinrich, MC
    Tuveson, DA
    Singer, S
    Janicek, M
    Fletcher, JA
    Silverman, SG
    Silberman, SL
    Capdeville, R
    Kiese, B
    Peng, B
    Dimitrijevic, S
    Druker, BJ
    Corless, C
    Fletcher, CDM
    Joensuu, H
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) : 472 - 480
  • [2] DiPaola RS, 1997, CANCER GENE THER, V4, P176
  • [3] CD 117 (KIT): A diverse protein with selective applications in surgical pathology
    Gibson, PC
    Cooper, K
    [J]. ADVANCES IN ANATOMIC PATHOLOGY, 2002, 9 (01) : 65 - 69
  • [4] Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
    Heinrich, MC
    Griffith, DJ
    Druker, BJ
    Wait, CL
    Ott, KA
    Zigler, AJ
    [J]. BLOOD, 2000, 96 (03) : 925 - 932
  • [5] Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
    Heinrich, MC
    Corless, CL
    Demetri, GD
    Blanke, CD
    von Mehren, M
    Joensuu, H
    McGreevey, LS
    Chen, CJ
    Van den Abbeele, AD
    Druker, BJ
    Kiese, B
    Eisenberg, B
    Roberts, PJ
    Singer, S
    Fletcher, CDM
    Silberman, S
    Dimitrijevic, S
    Fletcher, JA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) : 4342 - 4349
  • [6] Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis
    Huang, S
    Jean, D
    Luca, M
    Tainsky, MA
    Bar-Eli, M
    [J]. EMBO JOURNAL, 1998, 17 (15) : 4358 - 4369
  • [7] Huang SY, 1996, ONCOGENE, V13, P2339
  • [8] PROGRESSION OF HUMAN CUTANEOUS MELANOMA IS ASSOCIATED WITH LOSS OF EXPRESSION OF C-KIT PROTOONCOGENE RECEPTOR
    NATALI, PG
    NICOTRA, MR
    WINKLER, AB
    CAVALIERE, R
    BIGOTTI, A
    ULLRICH, A
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1992, 52 (02) : 197 - 201
  • [9] c-KIT receptor expression in cutaneous malignant melanoma and benign melanocytic naevi
    Ohashi, A
    Funasaka, Y
    Ueda, M
    Ichihashi, M
    [J]. MELANOMA RESEARCH, 1996, 6 (01) : 25 - 30
  • [10] Drug therapy: Imatinib mesylate - A new oral targeted therapy.
    Savage, DG
    Antman, KH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) : 683 - 693